Capricor Therapeutics Inc (NASDAQ: CAPR) surged 390.02% to $31.16 on December 3rd, despite concerns from Martin Shkreli and others about potential fraud. This extreme volatility highlights the high risk of shorting biotech stocks, even when fundamental concerns exist. Investors should exercise extreme caution with CAPR given the significant price movement and underlying fraud allegations.